Intech Investment Management LLC bought a new stake in Coherus BioSciences, Inc. (NASDAQ:CHRS – Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with ...

Amgen’s Neulasta is set to face its first competition in the US after the FDA approved Mylan’s biosimilar version of the blockbuster cancer infection biologic. Neulasta brought in $4.5 billion ...

Napp’s Pelmeg, a biosimilar of Amgen’s cancer drug Neulasta (pegfilgrastim), has been launched in the UK following approval late last year. This is Napp’s first launch of a product developed ...

Coherus BioSciences will see its workforce shrink once again as the result of the recently agreed sale of its Neulasta biosimilar to Accord BioPharma. About 50 employees who are associated with ...

With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that ...

Pegfilgrastim biosimilars, including Neulasta, are instrumental in preventing chemotherapy-induced neutropenia by stimulating white blood cell production and reducing infection risks. The Neulasta ...

In addition to the antibiotics, Sunshine Biopharma is preparing to launch 13 more drugs in Canada in 2025, including NIOPEG®, a biosimilar of NEULASTA®, which helps reduce infection in certain ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Among the new drugs to be launched is NIOPEG®, a biosimilar of NEULASTA®. Like NEULASTA®, NIOPEG® is a long-acting form of recombinant human granulocyte colony-stimulating factor (filgrastim).

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.